John Greene Biography and Net Worth

Director of CRISPR Therapeutics

John T. Greene has served on our Board of Directors since June 2019. He currently serves as Executive Vice President and Chief Financial Officer of Discover, where he has been employed since 2019. Prior to joining Discover, John served Executive Vice President and Chief Financial Officer and Treasurer at Bioverativ, a global biopharmaceutical company. From 2014 to 2016, he was the Chief Financial Officer for Willis Group Holdings, which was preceded by more than eight years at HSBC Holdings where he held Chief Financial Officer positions for several divisions, including retail bank and wealth management; insurance and consumer and mortgage lending. He also held various Chief Financial Officer roles in his 12-year tenure with General Electric from 1993 to 2005. He holds a bachelor’s degree in accounting from the State University of New York and an M.B.A. from the Kellogg School of Management at Northwestern University.

What is John Greene's net worth?: The estimated net worth of John Greene is at least $407.26 thousand as of February 26th, 2025. Greene owns 7,000 shares of CRISPR Therapeutics stock worth more than $407,260 as of December 5th. This net worth estimate does not reflect any other investments that Greene may own. Learn More about John Greene's net worth.
How do I contact John Greene?: The corporate mailing address for Greene and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on John Greene's contact information.
Has John Greene been buying or selling shares of CRISPR Therapeutics?: John Greene has not been actively trading shares of CRISPR Therapeutics over the course of the past ninety days. Most recently, on Wednesday, February 26th, John Greene bought 7,000 shares of CRISPR Therapeutics stock. The stock was acquired at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the transaction, the director now directly owns 7,000 shares of the company's stock, valued at $313,950. Learn More on John Greene's trading history.
Who are CRISPR Therapeutics' active insiders?: CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Simeon George (Director), John Greene (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), Naimish Patel (Chief Medical Officer), Raju Prasad (CFO), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.
Are insiders buying or selling shares of CRISPR Therapeutics?: In the last year, CRISPR Therapeutics insiders bought shares 2 times. They purchased a total of 996,812 shares worth more than $51,813,868.36. In the last year, insiders at the sold shares 8 times. They sold a total of 92,526 shares worth more than $5,560,017.15. The most recent insider tranaction occured on October, 17th when CEO Samarth Kulkarni sold 50,895 shares worth more than $3,456,279.45. Insiders at CRISPR Therapeutics own 4.3% of the company. Learn More about insider trades at CRISPR Therapeutics.
Information on this page was last updated on 10/17/2025.

John Greene Insider Trading History at CRISPR Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/26/2025	Buy	7,000	$44.85	$313,950.00	7,000

John Greene Buying and Selling Activity at CRISPR Therapeutics

CRISPR Therapeutics Company Overview

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Today's Range

Now: $58.18

$54.93

$59.77

50 Day Range

MA: $61.39

$49.29

$76.78

2 Week Range

Now: $58.18

$30.04

$78.48

Volume

3,099,579 shs

Average Volume

2,391,821 shs

Market Capitalization

$5.54 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74